title: Immunoglobulin replacement therapy: a twenty-year review and current update.
abstract: OBJECTIVE
  The expansion of immunoglobulin replacement to multiple disease entities marks a decade-long advancement in immune therapy. Parallel to its extension, the characteristics and composition of immunoglobulin products have diversified. The aim of this study was to summarize a 20-year comprehensive literature review of currently commercially available immunoglobulin products, particularly examining individual product properties in a comparative format. Data Sources/Study Selections: The literature review was performed using PubMed and Ovid, screening a time span of 2 decades. Both authors reviewed the obtained articles for acceptable quality, and the selection was narrowed down based on criteria for randomized clinical and therapeutic trials.
  
  
  RESULTS
  Product-specific characteristics in terms of purification strategy, stabilizers, composition, and viral inactivation were found among the immunoglobulin products investigated. Such differing characteristics manifest in their variable clinical safety and efficacy as assessed by the comparative product analysis. In subgroups of patients, subcutaneous immunoglobulin therapy may be an alternative to intravenous immunoglobulin (IVIG) therapy with an equal efficacy and a lower number of systemic adverse events.
  
  
  CONCLUSIONS
  Only few comprehensive clinical synopses are available to clearly demonstrate the differences in IVIG products despite the widespread clinical use of the therapy. This review defines significant characteristics of individual immunoglobulin products, noting important differences in product development and application and allowing informed clinical decisions to match a product with patients' risk factors and comorbidity. This balanced approach to gammaglobulin replacement therapy is imperative to produce the highest clinical efficacy and lowest number of adverse events.
authors.affiliation: David Geffen School of Medicine, University of California, Los Angeles, Calif., USA.
authors.forename: Monika
authors.initials: M
authors.lastname: Saeedian
authors.forename: Inderpal
authors.initials: I
authors.lastname: Randhawa
mesh_terms: D000818:Animals; D006801:Humans; D007116:Immunization, Passive / Q000379:methods*; D016756:Immunoglobulins, Intravenous / Q000276:immunology / Q000494:pharmacology* / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
chemical_list: D016756:Immunoglobulins, Intravenous